U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Localized Prostate Carcinoma

MedGen UID:
1779081
•Concept ID:
C5447286
•
Neoplastic Process

Definition

A carcinoma that arises from the prostate and has not spread to other anatomic sites. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLocalized Prostate Carcinoma

Professional guidelines

PubMed

Minimally Invasive Procedures in the Diagnosis and Treatment of Localized Prostate Cancer: an Interventional Radiologist's Perspective.
Avital Y, Fütterer JJ, Cherniavsky A, Bomers JGR
Curr Oncol Rep 2022 Nov;24(11):1433-1441. Epub 2022 Jun 7 doi: 10.1007/s11912-022-01291-3. PMID: 35670993Free PMC Article
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS
Cancer 2005 Apr 15;103(8):1615-24. doi: 10.1002/cncr.20955. PMID: 15742331
Current status of minimally invasive treatment options for localized prostate carcinoma.
Beerlage HP, Thüroff S, Madersbacher S, Zlotta AR, Aus G, de Reijke TM, de la Rosette JJ
Eur Urol 2000 Jan;37(1):2-13. doi: 10.1159/000020091. PMID: 10671777

Recent clinical studies

Etiology

Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study.
Hass P, Fischbach F, Pech M, Gawish A
J Cancer Res Clin Oncol 2023 Jul;149(8):5397-5404. Epub 2022 Nov 29 doi: 10.1007/s00432-022-04491-3. PMID: 36445477Free PMC Article
Long-term outcome of biologically guided dose-escalated radiotherapy of localized prostate cancer.
Kuisma A, Wright P, Suilamo S, Seppälä J, Koivisto M, Lindholm P, Minn H
Acta Oncol 2022 Jan;61(1):97-103. Epub 2021 Nov 12 doi: 10.1080/0284186X.2021.1998613. PMID: 34772320
Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death.
Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam K, Veillard AS, Stricker P, Haupt S, Haupt Y, Horvath L, Fox SB
Ann Oncol 2014 Dec;25(12):2392-2397. Epub 2014 Sep 17 doi: 10.1093/annonc/mdu454. PMID: 25231954
Current status of minimally invasive treatment options for localized prostate carcinoma.
Beerlage HP, Thüroff S, Madersbacher S, Zlotta AR, Aus G, de Reijke TM, de la Rosette JJ
Eur Urol 2000 Jan;37(1):2-13. doi: 10.1159/000020091. PMID: 10671777
Is there a role for cryoablation of the prostate in the management of localized prostate carcinoma?
Long JP
Hematol Oncol Clin North Am 1996 Jun;10(3):675-90. doi: 10.1016/s0889-8588(05)70360-9. PMID: 8773504

Diagnosis

Minimally Invasive Procedures in the Diagnosis and Treatment of Localized Prostate Cancer: an Interventional Radiologist's Perspective.
Avital Y, Fütterer JJ, Cherniavsky A, Bomers JGR
Curr Oncol Rep 2022 Nov;24(11):1433-1441. Epub 2022 Jun 7 doi: 10.1007/s11912-022-01291-3. PMID: 35670993Free PMC Article
Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells.
Kyjacova L, Hubackova S, Krejcikova K, Strauss R, Hanzlikova H, Dzijak R, Imrichova T, Simova J, Reinis M, Bartek J, Hodny Z
Cell Death Differ 2015 Jun;22(6):898-911. Epub 2014 Jul 11 doi: 10.1038/cdd.2014.97. PMID: 25012501Free PMC Article
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS
Cancer 2005 Apr 15;103(8):1615-24. doi: 10.1002/cncr.20955. PMID: 15742331
Defining sexual outcomes after treatment for localized prostate carcinoma.
Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA
Cancer 2002 Oct 15;95(8):1773-85. doi: 10.1002/cncr.10848. PMID: 12365027
Clinical diagnosis of prostate cancer.
Schmidt JD
Cancer 1992 Jul 1;70(1 Suppl):221-4. doi: 10.1002/1097-0142(19920701)70:1+<221::aid-cncr2820701308>3.0.co;2-9. PMID: 1376191

Therapy

Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: Impact on management.
Tillier CN, Boekhout AH, Veerman H, Wollersheim BM, Groen P, van der Poel HG, van de Poll-Franse LV
Urol Oncol 2023 Nov;41(11):454.e1-454.e8. Epub 2023 Sep 9 doi: 10.1016/j.urolonc.2023.08.001. PMID: 37690935
Long-term outcome of biologically guided dose-escalated radiotherapy of localized prostate cancer.
Kuisma A, Wright P, Suilamo S, Seppälä J, Koivisto M, Lindholm P, Minn H
Acta Oncol 2022 Jan;61(1):97-103. Epub 2021 Nov 12 doi: 10.1080/0284186X.2021.1998613. PMID: 34772320
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS
Cancer 2005 Apr 15;103(8):1615-24. doi: 10.1002/cncr.20955. PMID: 15742331
Current status of minimally invasive treatment options for localized prostate carcinoma.
Beerlage HP, Thüroff S, Madersbacher S, Zlotta AR, Aus G, de Reijke TM, de la Rosette JJ
Eur Urol 2000 Jan;37(1):2-13. doi: 10.1159/000020091. PMID: 10671777
Is there a role for cryoablation of the prostate in the management of localized prostate carcinoma?
Long JP
Hematol Oncol Clin North Am 1996 Jun;10(3):675-90. doi: 10.1016/s0889-8588(05)70360-9. PMID: 8773504

Prognosis

Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer.
Ahmad Khalil D, Jazmati D, Geismar D, Wulff J, Bäumer C, Kramer PH, Steinmeier T, Schulze Schleitthoff S, Plaude S, Bischoff M, Tschirdewahn S, Hadaschik B, Timmermann B
Radiat Oncol 2022 Apr 1;17(1):64. doi: 10.1186/s13014-022-02025-2. PMID: 35365170Free PMC Article
Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death.
Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam K, Veillard AS, Stricker P, Haupt S, Haupt Y, Horvath L, Fox SB
Ann Oncol 2014 Dec;25(12):2392-2397. Epub 2014 Sep 17 doi: 10.1093/annonc/mdu454. PMID: 25231954
Genetic profile identification in clinically localized prostate carcinoma.
Gallucci M, Merola R, Leonardo C, De Carli P, Farsetti A, Sentinelli S, Sperduti I, Mottolese M, Carlini P, Vico E, Simone G, Cianciulli A
Urol Oncol 2009 Sep-Oct;27(5):502-8. Epub 2008 Jun 4 doi: 10.1016/j.urolonc.2008.04.008. PMID: 18534873
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS
Cancer 2005 Apr 15;103(8):1615-24. doi: 10.1002/cncr.20955. PMID: 15742331
Defining sexual outcomes after treatment for localized prostate carcinoma.
Schover LR, Fouladi RT, Warneke CL, Neese L, Klein EA, Zippe C, Kupelian PA
Cancer 2002 Oct 15;95(8):1773-85. doi: 10.1002/cncr.10848. PMID: 12365027

Clinical prediction guides

Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study.
Hass P, Fischbach F, Pech M, Gawish A
J Cancer Res Clin Oncol 2023 Jul;149(8):5397-5404. Epub 2022 Nov 29 doi: 10.1007/s00432-022-04491-3. PMID: 36445477Free PMC Article
Long-term outcome of biologically guided dose-escalated radiotherapy of localized prostate cancer.
Kuisma A, Wright P, Suilamo S, Seppälä J, Koivisto M, Lindholm P, Minn H
Acta Oncol 2022 Jan;61(1):97-103. Epub 2021 Nov 12 doi: 10.1080/0284186X.2021.1998613. PMID: 34772320
Conversion and validation of rectal constraints for prostate carcinoma receiving hypofractionated carbon-ion radiotherapy with a local effect model.
Wang W, Li P, Sheng Y, Huang Z, Zhao J, Hong Z, Shahnazi K, Jiang GL, Zhang Q
Radiat Oncol 2021 Apr 13;16(1):72. doi: 10.1186/s13014-021-01801-w. PMID: 33849589Free PMC Article
Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death.
Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam K, Veillard AS, Stricker P, Haupt S, Haupt Y, Horvath L, Fox SB
Ann Oncol 2014 Dec;25(12):2392-2397. Epub 2014 Sep 17 doi: 10.1093/annonc/mdu454. PMID: 25231954
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.
Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS
Cancer 2005 Apr 15;103(8):1615-24. doi: 10.1002/cncr.20955. PMID: 15742331

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...